Indietro

Bristol-Myers Squibb Company

Ticker: BMY ISIN: US1101221083
Aggiungi al portafoglio Analisi del portafoglio in 2min
Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high
Capitalizzazione
117,46 Mld $
P/E
16,11
Forward P/E
9,12
Profit margin
15,01%
Revenue growth QoQ
2,60%
Div. yield
4,51%
Beta
0,24
67,92 $ 0,95%
Prezzo al 2026-08-25 · NYSE

Performance per periodo

Rendimenti cumulativi
1 Month +8,57%
6 Months +13,21%
1 Year +50,77%
5 Years +4,59% p.a.+25,16%
10 Years +5,10% p.a.+64,41%
Since inception +4,65% p.a.+210,91%
Rendimenti per anno
YTD +30,17%
2025 +0,11%
2024 +15,81%
2023 -26,14%
2022 +18,98%
2021 +2,88%

Key stats

Market cap
117,46 Mld
P/E
16,11
Dividend yield
4,51%
Beta
0,24
52-week range
41.46 - 62.25
50-day MA
57,09
200-day MA
53,80
Section 1

Business overview

Company profile data from fundamentals.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - General
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 38,73%
ROA 10,69%
Profit margin 15,01%
Operating margin 33,04%
PEG ratio 1,49
Revenue/share TTM 23,82
Revenue TTM 48,48 Mld
EBITDA 18,97 Mld
Gross profit TTM 34,90 Mld
Beta 0,24

Valuation

Trailing P/E 16,11
Forward P/E 9,12
P/B 5,85
P/S 2,42
EV/EBITDA 10,23
EV/Revenue 3,16

ESG Scores

Total ESG 29,2
Environment 3,8
Social 18,8
Governance 14,0
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 6,31
Quarterly earnings growth 9,20%
Revenue TTM 48,48 Mld
Reported quarters 119
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 4,51%
Forward annual div. yield 5,62%
Dividend per share 2,5000
Payout ratio 36,85%
Ex-dividend date 2025-10-03
Next dividend date 2026-08-03
Split factor 1000000:951777
Last split date 2001-08-07
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 53,00 $
Analyst rating 3.3704

Ownership & short interest

Shares outstanding 2,04 Mld
Shares float 2,03 Mld
Institutional ownership 82,79%
Insider ownership 7,20%
Short ratio 3,46
Short % of float 1,94%

Details

Instrument metadata and source update timestamps.

Symbol BMY
Name Bristol-Myers Squibb Company
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US1101221083
Country USA
Code + exchange BMY.NYSE
Last price date 2026-06-26
Fundamentals updated 2026-06-29

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.